Cutting-Edge Research Anticipated at Society for Immunotherapy of Cancer’s 34th Annual Meeting

Nov. 5, 2019

MILWAUKEE – Leading experts in tumor immunology and cancer immunotherapy will gather to share cutting-edge basic and translational research, and emerging clinical data, at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, Nov. 7–10, in National Harbor, Md.

As the premier destination for scientific exchange, education and networking in the cancer immunotherapy field, the society’s 34th Annual Meeting & Pre-Conference Programs (SITC 2019) is set to attract more than 4,000 attendees, uniting researchers, clinicians, pharmacists and others to learn and discuss the latest breakthroughs in the field of cancer immunotherapy.

Featured below are select abstracts, including author and presentation information, that will be presented at SITC 2019.

A phase 1 dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies

Abstract O84
Session 304: Late-Breaking Abstract Session
Saturday, Nov. 9, at 11:50 a.m. EST, Potomac Ballroom

Sarina A. Piha-Paul, MD

  • This phase 1 study of a HER2/4-1BB bispecific molecule aims to evaluate the safety and recommended phase 2 dose of the agent in patients with HER2+ malignancies. As the first bispecific targeting 4-1BB (a costimulatory immune receptor) to enter clinical testing, dose levels from 0.0005 to 8 mg/kg have been tested, and results will be presented at the meeting.

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) monotherapy vs platinum-based chemotherapy (chemo) as first-line (1L) treatment in PD-L1-selected NSCLC

Abstract O83
Session 304: Late-Breaking Abstract Session
Saturday, Nov. 9, at 11:50 a.m. EST, Potomac Ballroom

Giuseppe Giaccone, MD, PhD

  • IMpower110 compares first-line treatment with 1200 mg atezolizumab Q3W to platinum-based chemotherapy in squamous and nonsquamous non-small cell lung cancer patients with PD-L1 expression of at least 1%. The primary endpoint of overall survival (tested hierarchically by PDL1 expression) will be presented at the meeting, after a median follow-up of over one year.

Final results from a phase 2 study using off-the-shelf activated natural killer (aNK) cells in combination with N-803, an IL-15 superagonist, in patients with metastatic Merkel cell carcinoma (MCC)

Abstract O19
Concurrent Session 209: Virus Driven Cancers
Friday, Nov. 8, at 4:50 p.m. EST, National Harbor 10–11

Shailender Bhatia, MD

  • As natural killer (NK) cells can eliminate tumors with deficient MHC-I, a common evasion mechanism for Merkel cell carcinoma, they hold potential for treatment of this disease. This study evaluated activated NK cells either as monotherapy or in combination with an IL-15 superagonist. The results from this study will be presented, laying the groundwork for future investigation of this agent.

Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers

Abstract O40
Session 204: Immune Checkpoints: Newer Targets and Updates on Combinations
Friday, Nov. 8, at 2 p.m. EST, Potomac Ballroom

Jason J. Luke, MD, FACP

  • Through blocking CD73 enzyme activity, CPI-006 modulates immune activity such as lymphocyte activation, T and B cell trafficking, and marker expression on antigen-presenting cells. This phase 1/1b study evaluated CPI-006 as monotherapy or in combination with ciforadenant, and results including safety, immunology, and preliminary efficacy will be presented.

Onsite registration for SITC 2019 begins today, Nov. 5, 2019, at the Gaylord National Hotel & Convention Center in National Harbor, Md. To learn more about SITC 2019, review late-breaking and regular abstract titles and more, please visit the SITC 2019 Annual Meeting website.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at and follow us on TwitterLinkedInFacebook and YouTube.


Media Contact

Julia Schultz, Director of Communications
(414) 271-2456